INJECTABLE DRUG DELIVERY MARKET ANALYSIS

Injectable Drug Delivery Market - Global Forecast to 2026, by Device Type (Prefilled Syringes, Auto Injectors, Pens, Conventional Syringes, Cartridges, Ampoules, Vials, and Others), by Material Type (Glass and Plastic), by Usability (Disposable and Reusable), by Route of Administration (Intravenous, Intramuscular, and Subcutaneous), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

Published In : Jun 2019
Code : CMI2768
Pages :262
Formats :
Excel and PDF
Industry : Medical Devices

Regional Analysis

Figure 1. Global Injectable Drug Delivery Market Value (US$ Mn), by Region, 2017

Increasing product approval and launch in North America is expected to bolster the market growth

North America holds dominant position in the global injectable drug delivery market, owing to increased focus of regional players in research and development and product launches. In 2017, Bayer received U.S. Food and Drug Administration (FDA) approval for a connected auto-injector-BETACONNECT for relapsing-remitting multiple sclerosis medication and companion app- myBETAapp. The app allows patients to automatically have a record of all their injections and share that record with their nurse or physician. Similarly, in October 2018, Genentech announced the U.S. Food and Drug Administration (FDA) approval for single-dose prefilled syringes (PFS) for Xolair (omalizumab) as an additional formulation for both allergic asthma and chronic idiopathic urticaria (CIU) indications.

Moreover, increasing incidence of chronic diseases such as anaphylaxis, diabetes, and cardiac arrest in the region is expected to support growth of the market during the forecast period. For instance, according to Journal of Allergy and Clinical Immunology, 2014, prevalence of anaphylaxis in the U.S. was 1.6% in the general population, while the number of hospitalizations associated with the disease is ever increasing in the U.S.